Narcolepsy Drugs Market Report 2026

Narcolepsy Drugs Market Overview

• Narcolepsy Drugs market size has reached to $3.94 billion in 2025 • Expected to grow to $5.93 billion in 2030 at a compound annual growth rate (CAGR) of 8.3% • Growth Driver: Growing Demand For Personalized Medicine Fuels Narcolepsy Drugs Market Expansion • Market Trend: Advancements In Extended-Release Therapeutics Revolutionize Narcolepsy Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Narcolepsy Drugs Market?

Narcolepsy drugs are medications specifically designed to manage and alleviate the symptoms of narcolepsy, a chronic neurological disorder characterized by excessive daytime sleepiness (EDS), sudden episodes of muscle weakness or paralysis (cataplexy), sleep paralysis, and hallucinations. These medications are often used in combination and tailored to the individual needs of the patient, aiming to improve quality of life by reducing the severity of narcolepsy symptoms. The main types of narcolepsy drugs are narcolepsy with cataplexy, narcolepsy without cataplexy, and secondary narcolepsy. Narcolepsy with Cataplexy is a type of narcolepsy where individuals experience sudden, temporary muscle weakness or paralysis triggered by strong emotions such as laughter, surprise, or anger. The various diseases include daytime extreme sleepiness, cataplexia, and other diseases used by various therapeutics such as sodium oxybate, central nervous system stimulants, tricyclic antidepressants, selective serotonin reuptake inhibitors, and other therapeutics.

What Is The Narcolepsy Drugs Market Growth Forecast?

The narcolepsy drugs market size is expected to see strong growth in the next few years. It will grow to $5.93 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to rising development of novel therapeutics, increasing investment in neurology research, growing demand for personalized medicine, expansion of extended-release formulations, increasing global narcolepsy diagnosis rates. Major trends in the forecast period include increasing adoption of novel wakefulness-promoting agents, growing use of combination therapy for symptom control, rising diagnosis rates due to improved awareness, expanding treatment options for cataplexy and eds, development of long-acting and extended-release drug formulations.

What Is The Driver Of The Narcolepsy Drugs Market?

The growing demand for personalized medicine is expected to propel the growth of the narcolepsy drugs market going forward. Personalized medicine refers to a medical care philosophy that aims to tailor medicines and interventions to the particular requirements of each patient. The demand for personalized medicine is due to the rapid growth of omics technology, data integration, genetics, and an awareness of the significance of tailored patient-specific medications and preventive actions. Narcolepsy drugs are used in personalized medicine for tailoring treatment plans to individual patient needs, considering genetic profiles, symptom severity, metabolic rates, and personal preferences to optimize effectiveness and minimize side effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the USFDA approved 16 new personalized treatments for rare disease patients in 2023, a significant increase from 6 personalized treatments in 2022. Therefore, the growing demand for personalized medicine drives the growth of the narcolepsy drugs industry.

Key Players In The Global Narcolepsy Drugs Market

Major companies operating in the narcolepsy drugs market are Jazz Pharmaceuticals plc, Harmony Biosciences Holdings Inc, Avadel Pharmaceuticals plc, Teva Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Ltd, Axsome Therapeutics Inc, NLS Pharmaceutics Ltd, Alkermes plc, Bioprojet Pharma sarl, Arena Pharmaceuticals Inc, Novartis AG, Shionogi Inc, Rhodes Pharmaceuticals LP, Janssen Global Services LLC, Eli Lilly and Company, Centessa Pharmaceuticals UK Ltd, Azurity Pharmaceuticals Inc, Amneal Pharmaceuticals Inc, Hikma Pharmaceuticals plc, Sunovion Pharmaceuticals Inc, Addrenex Pharmaceuticals Inc, Graymark Healthcare Inc, Theranexus, Suven Life Sciences

Global Narcolepsy Drugs Market Trends and Insights

Major companies operating in the narcolepsy drugs market are developing innovative products, such as extended-release therapeutics, to enhance treatment efficacy and patient experience. Extended-release (ER) therapeutics offer significant benefits for patients with narcolepsy by improving medication adherence, maintaining stable drug levels, reducing side effects, and enhancing overall symptom management. For instance, in May 2023, Avadel Pharmaceuticals, an Ireland-based specialty pharmaceutical company, launched Lumryz, an extended-release sodium oxybate medication approved by the Food and Drug Administration (FDA), a US-based federal agency. Lumryz features an innovative extended-release mechanism that allows patients to maintain consistent therapeutic levels overnight with a single dose, enhancing convenience and compliance compared to traditional multiple-dose regimens. This new medication addresses a significant unmet need by simplifying treatment schedules, potentially improving patient adherence and overall quality of life for those managing narcolepsy.

What Are Latest Mergers And Acquisitions In The Narcolepsy Drugs Market?

In October 2025, Viatris Inc., a US-based global healthcare company, acquired Aculys Pharma, Inc. for an undisclosed amount. With this acquisition, Viatris aims to bolster its central nervous system (CNS) portfolio in Japan and key Asia-Pacific markets by gaining development and commercialization rights to two innovative neurological assets. Aculys Pharma is a Japan-based clinical-stage biopharmaceutical company focused on commercializing novel CNS therapies, including pitolisant and Spydia (diazepam) nasal spray.

What Defines the Narcolepsy Drugs Market?

The narcolepsy drugs market consists of sales of orexin receptor antagonists, stimulants, and orexin-based therapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Narcolepsy Drugs Market Report 2026?

The narcolepsy drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the narcolepsy drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.